Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,050 recruiting studies in this area right now.
By phase
- Not applicable2,999
- Phase 21,056
- Phase 1792
- Phase 1/Phase 2437
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes130
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland199
- Alabama178
- Florida149
- Arizona148
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,050 total
- NCT07518446Recruiting
Health Screening for Adults Starting Psychiatric Care
This study checks the physical health of adults beginning treatment for serious mental illnesses like schizophrenia or depression at two Danish clinics. It aims to catch health problems early that people with these conditions often experience.
CopenhagenAges 18 years+ - NCT07516769RecruitingPhase 3
Nicorandil to reduce inflammation in active rheumatoid arthritis
This study tests whether nicorandil, a heart medication with anti-inflammatory properties, can help reduce joint inflammation and swelling in people with active rheumatoid arthritis who are already taking conventional disease-modifying drugs. The goal is to see if it provides additional relief from symptoms.
Tanta, Gharbia GovernorateAges 18–70 - NCT07524244Recruiting
Ketogenic and carnivore diets for IBD and rheumatoid arthritis
This study tests whether special diets (ketogenic or carnivore/meat-based) can help reduce inflammation and symptoms in people with inflammatory bowel disease or rheumatoid arthritis. You'll follow dietary guidelines for 3 weeks, then continue in the study while researchers track how you respond.
Charlottesville, VirginiaAges 18–64 - NCT07516548Recruiting
Long-acting HIV prevention and birth control study
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
Bontleng, GaboroneAges 18 years+ - NCT07522905Recruiting
Virtual Movement Therapy for Kids With Leukemia in Remission
This study tests a fun virtual movement program where children who have finished leukemia treatment exercise together with a healthy friend online. The goal is to help improve their physical strength, coordination, and social skills after cancer treatment.
BratislavaAges 5–12 - NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT06759181RecruitingPhase 1/Phase 2
CAR-T targeting BCMA and FcRL5 for relapsed/refractory myeloma
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
XuzhouAges 18–70 - NCT06759831Recruiting
Clinical outcomes of living and deceased donor kidney transplants
This study looks at how well kidney transplants work from both living and deceased donors. It may help doctors better understand long-term outcomes for people who get a new kidney.
Bologna, BOAges 18 years+ - NCT07513181RecruitingPhase 2
Testing ATH-063 for Hard-to-Treat Ulcerative Colitis
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
Miami, FloridaAges 18–75 - NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
La Jolla, CaliforniaAges 18–18 - NCT07516093RecruitingPhase 3
Comparing two drugs for advanced CLL or SLL
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
Macon, GeorgiaAges 18 years+ - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06758817Recruiting
Nutrition, gut health, and rheumatoid arthritis study
This trial tests if a specific diet can improve your rheumatoid arthritis symptoms by affecting your gut bacteria. You may be eligible if you have active RA and are willing to follow a special meal plan for several weeks.
Lisbon, PortugalAges 18 years+ - NCT04672733Recruiting
Switch from IVIg to Hizentra for CIDP nerve inflammation
This study tests Hizentra® as an alternative to IV immunoglobulin (IVIg) for adults with CIDP, a condition where the immune system damages the nerves. You may be able to switch to Hizentra if your current IVIg treatment is keeping your CIDP stable and you can switch safely.
AmiensAges 18 years+ - NCT07509749RecruitingPhase 2
New treatments for severe acute GVHD after stem cell transplant
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
BeijingAges 14 years+ - NCT07514819Recruiting
Adaptive Proton Therapy Planning for Children With Cancer
This study tests a new way to plan proton radiation therapy (a precise type of cancer treatment) for children with solid tumors or Hodgkin's lymphoma. The goal is to improve how doctors adapt treatment during therapy to better target tumors while protecting healthy tissue.
Memphis, TennesseeAges Any age - NCT07508995RecruitingPhase 2
New pill combo for untreated chronic lymphocytic leukemia
This trial tests a new pill combination for chronic lymphocytic leukemia (CLL) that has not been treated before. The drugs are designed to attack CLL cells in two different ways to try to improve outcomes.
Houston, TexasAges 18 years+ - NCT07509086RecruitingPhase 2
Enhanced CAR-T therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
Changchun, JilinAges 18–80 - NCT07508605RecruitingPhase 1/Phase 2
CD19/CD20 CAR/TRuC-T cells for lymphoma that returned or didn't respond
This trial tests a new type of immune cell therapy that targets two markers (CD19 and CD20) on your lymphoma cells. It is for people whose lymphoma came back or didn't respond to previous treatments, including CD19 CAR-T therapy.
Shenzhen, GuangdongAges 18–75 - NCT07508280Recruiting
Energy-saving vs circuit training for asthma patients
This trial compares two exercise programs to see which helps people with asthma more. You may join if your asthma is mild to moderate and you do not have other serious conditions.
Jhang, Punjab ProvinceAges 30–50
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,050 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,115 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.